| News | Events |
| Publications | Companies |
| Clinical Trials |
RNAi in Plasmodium. Curr Pharm Des. 2013 May 16; Authors: Mueller AK, Hammerschmidt-Kamper C, Kaiser A Abstract RNA interference (RNAi) has quickly proven to be an immensely useful tool for studying gene function and validation of potential drug targets in almost all organisms that possess the required set of proteins...
Contine Reading & Discuss→Increase of PPAR by dopamine mediated via DA-1 receptor-linked phospholipase C pathway in neonatal rat cardiomyocytes. Auton Neurosci. 2013 May 20; Authors: Lo SH, Lee KS, Chen LJ, Cheng JT, Chen CH Abstract BACKGROUND: Role of peroxisome proliferator-activated receptor (PPAR) in cardiac contraction has recently been established. Dopamine is one...
Contine Reading & Discuss→MAVS-mediated host cell defense is inhibited by Borna Disease Virus. Int J Biochem Cell Biol. 2013 May 20; Authors: Li Y, Song W, Wu J, Zhang Q, He J, Li A, Qian J, Zhai A, Hu Y, Kao W, Wei L, Zhang F, Xu D Abstract Viruses often have strategies...
Contine Reading & Discuss→Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent 'type I' mode. Cell Death Dis. 2013;4:e643 Authors: Gillissen B, Richter A, Richter A, Overkamp T, Essmann F, Hemmati PG, Preissner R, Belka C, Daniel PT Abstract TRAIL is a promising anticancer agent,...
Contine Reading & Discuss→The Involvement of Mitochondrial Amidoxime Reducing Components 1 and 2 and Mitochondrial Cytochrome b5 in N-reductive Metabolism in Human Cells. J Biol Chem. 2013 May 23; Authors: Plitzko B, Ott G, Reichmann D, Henderson CJ, Wolf CR, Mendel R, Bittner F, Clement B, Havemeyer A Abstract The mitochondrial amidoxime reducing...
Contine Reading & Discuss→